Elucidation of the mechanism of oral tolerance induction to the transgenic rice containing peptides from Japanese cedar pollen allergens and the efficacy of long-term administration.

Not Applicable

• Conditions: Japanese cedar pollinosis

• Registration Number: JPRN-UMIN000034280
• Lead Sponsor: The Jikei University School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-09-26
• Study Completion: 2019-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Not provided

Exclusion Criteria

1) A person who is allergic to Rice or has a history of Rice allergy. 2) A person who shows House dust specific IgE antibody valued over Class V, and has chronic rhinitis 3) A person who is imperative to use medicine such as anti-allergic agent and steroidal chemicals that potentially influence the outcome of evaluation. 4) A person who underwent an operation that is accompanied to nasal disorder within last 2years, or has nasal disorder such as acute/chronic-rhinitis, rhinopolypus, hypertronic rhinitis, septal deviation, sinusitis which all are potentially hinder to the outcome of evaluation. 5) A person who has any disorders under treatment and the condition is unstable that trial investigator has asessed as mismatched participant. 6) A person who has a history of serious disorder such as diabetes, hepatic disorder, kidney disorder, and cardiac disorder. 7) A person who takes beta-blocker in order to treat complecating disorders such as hypertension, and / or cardiac disorder. 8) A person who takes alpha-blocker in order to treat complecating disorders such as prostatic hyperplasia. 9) A person who is complecated by immunodeficiency disorder, cancer, or severe enemia. 10) A person who is complecated by asthma. 11) A person who has laboratory abnormalities in the pre-clinical test that trial investigator has assessed as mismatched participant. 12) A person already in another clinical test when this clinical test begins. 13) A person who is presently breastfeeding, pregnant, or planning/wishing to be a pregnant during a period of this clinical test. 14) A person whom trial investigator has asessed as mismatched participant.

Study & Design

• Study Type: Interventional
• Study Design: Not specified